Short bowel syndrome market to approach $6.01 billion by 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Short Bowel Syndrome Market Projected To Reach By 2030?

The market for short bowel syndrome has seen rapid expansion in recent years. It is anticipated to expand from $3.08 billion in 2025 to $3.53 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 14.6%. The factors contributing to this growth historically include the increasing prevalence of short bowel syndrome, the limited treatment options available in the past, the reliance on parenteral nutrition, a rise in gastrointestinal surgeries, and growing hospital awareness.

The market for short bowel syndrome is projected to experience swift expansion in the coming years, anticipated to reach a valuation of $6.02 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 14.2%. Key factors driving this growth during the forecast period include the creation of new therapeutic options, wider access to home infusion services, individualized treatment strategies, the incorporation of microbiome-based therapies, and a rise in clinical trials for SBS treatments. Significant trends expected in the forecast period encompass an increase in parenteral nutrition solutions, the ongoing development of therapies for intestinal rehabilitation, the implementation of innovative surgical procedures, an amplified focus on modulating the gut microbiome, and the broadening of patient support initiatives.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23515&type=smp

What Major Factors Are Driving The Short Bowel Syndrome Market Forward?

The rising incidence of gastrointestinal conditions is anticipated to fuel expansion in the short bowel syndrome market in the coming period. These illnesses encompass a wide spectrum of ailments impacting the digestive system, such as those affecting the stomach, intestines, liver, and pancreas, frequently resulting in hindered digestion and diminished nutrient uptake. The escalating occurrence of gastrointestinal disorders is primarily fueled by poor dietary choices that compromise gut well-being and encourage inflammation. Gastrointestinal ailments can lead to the emergence of short bowel syndrome, often requiring the surgical excision of impaired intestinal parts, which in turn diminishes the body’s capacity for absorption. As an illustration, data from September 2023 provided by the Inflammatory Bowel Disease (IBD) Clinical and Research Centre, a Canadian organization dedicated to enhancing the lives of individuals with Crohn’s disease and ulcerative colitis, revealed that in 2023, over 320,000 people in Canada were living with inflammatory bowel disease (IBD), exhibiting a prevalence of 825 per 100,000. With an anticipated annual increase in prevalence of 2.44%, projections indicate that 1.1% of the Canadian population, equating to 470,000 individuals, will be affected by IBD by 2035. Consequently, the rising occurrence of gastrointestinal diseases is a key factor propelling the expansion of the short bowel syndrome market.

Which Segments Define The Short Bowel Syndrome Market Segment Structure?

The short bowel syndrome market covered in this report is segmented –

1) By Type: Glucagon-Like Peptide (GLP-2), Growth Hormone, Glutamine

2) By Diagnosis: Physical Exam, Blood Tests, Fecal Fat Tests, Imaging Procedures, Other Diagnosis

3) By Treatment: Nutritional Therapy, Medications, Surgery, Transplant

4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Other Distribution Channels

Subsegments:

1) By Glucagon-Like Peptide (GLP-2): Teduglutide, Other GLP-2 Analogues

2) By Growth Hormone: Somatropin, Other Growth Hormone Therapies

3) By Glutamine: Oral Glutamine, Intravenous Glutamine

Which Trends Are Impacting The Progress Of The Short Bowel Syndrome Market?

Leading companies in the short bowel syndrome market are concentrating on advancing medical science through innovations like treatments for intestinal failure, aiming to provide an enhanced therapeutic option that improves patient outcomes for those with gastrointestinal disorders. Intestinal failure represents a severe condition where the small intestine cannot adequately absorb nutrients, fluids, and electrolytes crucial for maintaining proper hydration and nutrition. For instance, in May 2024, Ironwood Pharmaceuticals, Inc., a US-based healthcare entity, disclosed new data from studies evaluating apraglutide in adults diagnosed with short bowel syndrome and intestinal failure (SBS-IF). As a next-generation GLP-2 analog, apraglutide exhibited potential to improve intestinal absorption and lessen dependence on parenteral support. These results emphasize the drug’s effectiveness, safety, and sustained advantages, reflecting Ironwood’s dedication to developing inventive treatments for gastrointestinal conditions.

Who Are The Established Players Within The Short Bowel Syndrome Market?

Major companies operating in the short bowel syndrome market are Nestlé SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co Ltd, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc, OxThera Inc, EnteraBio Ltd, GLyPharma Therapeutic Inc, Fresenius Kabi AG, Danone S A, B Braun Melsungen AG, Medtronic plc

Get The Full Short Bowel Syndrome Market Report:

https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

Which Region Is The Largest In The Short Bowel Syndrome Market?

North America was the largest region in the short bowel syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the short bowel syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Short Bowel Syndrome Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/short-bowel-syndrome-global-market-report

Browse Through More Reports Similar to the Global Short Bowel Syndrome Market 2026, By The Business Research Company

Bowel Management Systems Market Report 2026

https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report

Inflammatory Bowel Disease Treatment Market Report

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Ulcerative Colitis Market Report

https://www.thebusinessresearchcompany.com/report/ulcerative-colitis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795